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EDITORIAL
Evaluation before transcatheter aortic valve
implantation
Quel bilan avant implantation d’une valve aortique percutanée ?KEYWORDS
Aortic stenosis;
Transcatheter valve;
By March 2010, more than 14,000 patients had been treated with transcatheter aortic valve
implantation (TAVI), 8 years after the ﬁrst-in-man implantation performed in France in April
2002 [1]. Since then, after a long period of doubt, the technique has spread worldwide
with an enthusiastic response from cardiologists and surgeons and is being established inImaging
MOTS CLÉS
Rétrécissement
aortique ;
Valve percutanée ;
Imagerie
clinical practice. The devices and techniques have improved signiﬁcantly over the past
4 years, leading to a clear-cut decrease in complications, and the short- and mid-term
results appear excellent and comparable to surgery in a very selected population at high
surgical risk [2—9]. Since 2007, two devices have become commercially available in Europe,
the Edwards balloon-expandable bovine pericardium bioprosthesis (23 and 26mm sizes)
(Edwards Lifesciences, Irvine, CA, USA) and the Corevalve self-expandable porcine peri-
cardium bioprosthesis (26 and 29mm sizes) (Medtronic, Irvine, CA, USA). Both valves can
be implanted using the transfemoral arterial approach, whereas the transapical (Edwards)
and subclavian (Corevalve) routes are selected in cases of poor iliofemoral access. Reim-
bursement for TAVI, available in France since January 2010, has opened the door to a
greater number of procedures in our country, with subsequent investigations for optimal
screening.
The screening process is the key for a successful and safe TAVI procedure and has the
greatest impact upon the results. This process includes careful selection of patients on a
clinical basis and the use of a number of imaging procedures aimed at evaluating the techni-
cal feasibility of TAVI and selecting the best and safer approach. These elements constitute
a fundamental aspect of the training programmes offered by both companies supplying the
devices to each catheter valve team, which includes interventional cardiologists, cardiac
and vascular surgeons, anaesthesiologists, radiologists and echocardiographers.
The clinical indications for TAVI have been identiﬁed clearly in the European Associ-
ation of Cardio-Thoracic Surgery and European Society of Cardiology position statement
in 2008 [10], which gives clear recommendations on the current indication and appli-
cation of this emerging technique, and was recently reinforced in France by the Haute
Autorité de santé. To date, in view of the missing knowledge on long-term results,
TAVI should be restricted to patients with severe (< 1 cm2 or < 0.6 cm2/m2) and symp-
tomatic (NYHA functional class≥ 2) aortic stenosis who either have contraindications to
conventional aortic valve replacement by cardiac surgeons (i.e. porcelain aorta, hostile
thorax, multiple repeat surgery) or are considered at too high risk for surgery because
of associated comorbidities. This is mainly assessed by objective scoring to assess indi-
vidual risk, such as the EuroScore (> 20%) and/or the STS (Society of Thoracic Surgeons)
risk score (> 10%), and requires a multidisciplinary consensus. Other clinical parameters
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an be taken into account in particular cases, including
ge, clinical fragility, comorbidity-related life expectancy,
uality of life, autonomy and psychological status. The
hysician’s good clinical sense plays here an important role
n the ﬁnal decision to undertake the procedure and the
articipation of a geriatrician can be helpful in very old
atients.
Once the clinical indication has been conﬁrmed, the next
teps consist of evaluating the feasibility of the procedure,
aking into account the aortic valve anatomy, the coro-
ary artery and left ventricular status, then selecting the
est approach. In this regard, several imaging techniques
lay a crucial role, and reinforce the need for excellent
ooperation between echocardiographers and radiologists.
n addition to echocardiography, the role of computed
omography (CT) scanning is currently considered essential.
chocardiography, besides assessing the severity of aortic
tenosis, the anatomy of the valve, the distribution of cal-
ium over the leaﬂets and the left ventricular function, is
rucial for determining the diameter of the aortic annulus
nd hence the optimal valve size (annulus diameter between
8 and 24mm for the Edwards, between 20 and 27 for the
orevalve). Appropriate valve sizing is crucial to limit the
isk of valve embolization, annulus rupture or severe par-
valvular leak. This information can be obtained easily from
ransthoracic echocardiography and from transesophageal
chocardiography in the case of poor echogenicity, using the
ongitudinal view and measuring the distance separating the
alvular insertion sites. CT scan evaluation of the thoracic
orta is also important for assessment of the aorta anatomy
angulation, diameters and wall calciﬁcation) but in general
t overestimates the diameter of the aortic annulus, and is
ot considered an optimal tool for valve sizing.
On the other hand, the CT scan is mandatory for assess-
ent of the iliofemoral access, and must be obtained in
ll cases after simple preliminary evaluation of the same
y angiography. Three-dimensional reconstruction of the
rterial access provides a better way to document tortu-
sities and external calciﬁcation, whereas contrasted or
on-contrasted cross-sectional views are mandatory to cal-
ulate the internal diameters of the femoral and iliac
rteries as well as the intraluminal distribution of calcium.
nterestingly, only a few additional millilitres of contrast
edium are needed to permit visualization of the entire
orta, the take-off of the coronary arteries and the distance
rom the coronary ostia to the aortic annulus, thus providing
dditional important information before TAVI.
Once the patient is selected and planned for the pro-
edure, further evaluation may still be needed at the time
f valve implantation. Several supra-aortic angiograms may
e necessary to select the reference view that will be used
t the time of valve deployment, showing the aortic annu-
us perpendicular to the screen. This is crucial to visualize
he strip of calcium that will be used as a landmark for
alve positioning. Angiography combined with balloon inﬂa-
ion at the time of preimplantation valvotomy can be a key
or accurate valve sizing in cases of unsatisfactory annulus
easurement by echocardiography.
In summary, careful evaluation of patients is crucial
efore TAVI and is now quite a standardized process. It
equires close cooperation between the different special-Editorial
sts, starting with the referring cardiologist responsible
or the diagnosis and the timing for intervention, then
he medicosurgical team to evaluate the risk of surgical
VR, and ﬁnally the echocardiographers and radiologists to
nsure optimal screening of the patient and selection of
he ideal route. This process is time-consuming but essen-
ial to achieve a successful and safe procedure. A dedicated
oordinator is warranted to optimize this phase. Training
nd supervision are needed to educate each new team and
o help them start their programme with the best possible
hance of success.
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